Targeted AKT therapy has been proposed as an effective approach in cancer patients having germline PTEN mutations based on observations of durable complete tumor responses in two patients with metastatic breast cancer harboring different germline PTEN mutations who were treated with the catalytic AKT inhibitor capivasertib (both patients’ tumors had a total lack/markedly diminished PTEN staining) [8]. The gene discussed is PTEN; the disease is neoplasm.